Episode 18. Management of Smoldering Multiple Myeloma

Blood Cancer Talks

1. How I Approach Smoldering Myeloma (Vaxman and Gertz):

https://ashpublications.org/blood/article/140/8/828/485274

2. Risk-Stratification Models in SMM:

Mayo 2018 model: https://pubmed.ncbi.nlm.nih.gov/29895887/

PETHEMA (Spanish) model: https://pubmed.ncbi.nlm.nih.gov/17576818/

PANGEA model: https://pubmed.ncbi.nlm.nih.gov/36858677/

IMWG SMM model: https://pubmed.ncbi.nlm.nih.gov/33067414/

3. QuiRedex RCT (Lenalidomide-Dexamethasone vs Observation in High-Risk SMM):

https://pubmed.ncbi.nlm.nih.gov/36067617/

4. ECOG E3A06 RCT (Lenalidomide vs Observation in SMM):

https://pubmed.ncbi.nlm.nih.gov/31652094/

5. Intensive Treatment in High-Risk Smoldering Multiple Myeloma:

GEM-CESAR: https://ashpublications.org/blood/article/140/Supplement%201/292/490268

ASCENT: https://ashpublications.org/blood/article/140/Supplement%201/1830/492739

6. Current Clinical Trial Landscape in Smoldering Myeloma:

https://pubmed.ncbi.nlm.nih.gov/34114943/

7. How Light Chain Proteinuria Modulates Risk of Progression in Patients with sFLC ratio>100 as the only Myeloma-Defining Event?

https://pubmed.ncbi.nlm.nih.gov/35190659/